

Sheet 1 of 5

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ORGU-0023</b>	Serial No. <b>08/392,934</b>
		Applicant <b>R. S. Smith et al.</b>	
		Filing Date <b>October 28, 1996</b>	Group <b>1644</b>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Baer et al., "DNA Sequence and Expression of the B95-8 Epstein Barr Virus Genome, Nature 310: 207-211 (July 1984)	
*	AB	Basic and Clinical Immunology by D.P. Sites et al, Chapter 22 of the 4 <sup>th</sup> Edition, published by Lange Medical Publications of Los Altos CA (1982)	
MB1	AC	Burton et al., "A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals" Proc. Natl. Acad. Sci. USA Vol. 88: 10134-10137 (November 1991)	
*	AD	Coligan et al. Current Protocols in Immunology, Wiley Interscience, Units 12 and 2 (1991)	
*	AE	Current Protocols in Molecular Biology, Ausubel et al, eds. Wiley Interscience Press, (1989)	
MB1	AF	Curtiss, L.K. et al., "Localization of Two Epitopes of Apolipoprotein A-I That are Exposed on Human High Density Lipoproteins Using Monoclonal Antibodies and Synthetic Peptides", J. Biol. Chem., Vol. 263, No. 27: 13779-13785 (September 1988)	
MB1	AG	Diener et al., "Specific Immunosuppression by Immunotoxins Containing Daunomycin" Science Vol. 231: 148-150 (January 1986)	
x	AH	Dillner et al., "Antibodies Against a Synthetic Peptide Identify the Epstein-Barr Virus-Determined Nuclear Antigen" Proc. Natl. Acad. Sci USA 81: 4652-4656 (August 1984)	
*	AI	Douillard, J.Y. and Hoffman, T., Basic Facts about Hybridomas, in Compendium of Immunology, Vol. II, L. Schwartz, ed. (1981)	
MB1	AJ	Douillard, J.Y. and Hoffman, "Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors" T., Hybridoma 5 Supp 1: S139-S149 (July 1986)	
	AK	Eisenlohr et al., "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes" J. Exp Med. Vol. 175: 481-487 (February 1992)	
	AL	Fox et al., "Synthetic Peptide Derived From the Epstein-Barr Virus Encoded Early Diffuse Antigen (EA-D)-Reactive with Human Antibodies" J. Clin. Lab. Anal. 1:140-145 (1987)	
EXAMINER		DATE CONSIDERED 2/15/2003	

\* In view of the voluminous nature of this reference and the likelihood that this reference is available to the Examiner, a copy is not enclosed herewith.




<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ORGU-0023</b>	Serial No. <b>08/392,934</b>
		Applicant <b>R. S. Smith et al.</b>	
		Filing Date <b>October 28, 1996</b>	Group <b>1644</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
131	AM	Greiner et al., "Recombinant Interferon Enhances Monoclonal Antibody Targeting of Carcinoma Lesions in Vivo" Science Vol. 235, No. 4791: 895-898 (February 1987)	
8	AN	Gul Laboratories, EBV-EA Test, Product No. EA100 (1988, Revised July 1989)	
135	AO	Henle et al, "Epstein-Barr Virus Specific Diagnostic Tests in Infectious Mononucleosis" Human Pathology Vol. 5, No. 5: 551-565 (September 1974)	
	AP	Henle et al., "Demonstration of Two Distinct Components in the Early Antigen Complex of Epstein-Barr Virus-Infected Cells" Int. J. Cancer Vol. 8, No. 3: 272-282 (November 1971)	
	AQ	Herlyn et al., "Anti-Idiotypic Antibodies Bear the Internal Image of a Human Tumor Antigen" Science Vol. 232, No. 4746: 100-102 (April 1986)	
	AR	Hinuma, Y. et al., "Immunofluorescence and Herpes-Type Virus Particles in the P3HR-1 Burkitt Lymphoma Cell Line" J. Virol. Vol. 1, No.5: 1045-1051 (October 1967)	
	AS	Jackman et al., "Expression of Epstein-Barr Virus gp350 as a Single Chain Glycoprotein for an EBV Subunit Vaccine" Vaccine 17: 660-668 (1999)	
131	AT	Jemmerson, "Effects of Conformation, Amino Acid Sequence, and Carrier Coupling on the Immunological Recognition of Peptide and Protein Antigens" Effects on Immunological Recognition of Peptides in Medicine And Biology, Edited by Zegers, Boersma, Classen, CRC Press Inc., New York Chapter 16, 213-225 (1995)	
	AU	Köhler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" Nature: Vol. 256, No. 5517 495-497 (August 1975)	
	AV	Lenard, J. et al., "Use of Hydrogen Fluoride in Merrifield Solid-Phase Peptide Synthesis" J. Am. Chem. Soc. Vol. 89, No. 1: 181-182 (January 1967)	
8	AW	Lerner, "Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity" Nature 299: 592-596 (October 1982)	
131	AX	Luka et al., "A Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) Against the Major EBV-Associated Antigens. I. Correlation between ELISA and Immunofluorescence Titers Using Purified Antigens" J. Immunol. Methods 67: 145-156 (1984)	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 2/15/2003	



Sheet 3 of 5

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ORGU-0023</b>	Serial No. <b>08/392,934</b>
		Applicant <b>R. S. Smith et al.</b>	
		Filing Date <b>October 28, 1996</b>	Group <b>1644</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
ms	AY	Merrifield, "Solid Peptide Synthesis. I. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc. 85: 2149- 2154 (July 1963)	
ms	AZ	Oi et al., "Chimeric Antibodies", Bio Techniques Vol. 4, No. 3: 214-221 (May/June 1986)	
	BA	Ortho Diagnostic Systems, Inc. ORTHO *Epstein-Barr Virus EA(D+R)-IgG Antibody/ELISA Test for Detection of IgG Antibodies to the Early Antigen (EA) Diffuse and Restricted (D&R) Components of the Epstein-Barr Virus (EBV), Product Code 520025, 1-38 (Draft revised August 20, 1993)	
ms	BB	Pearson et al., "Application of Epstein-Barr Virus (EBV) Serology to the Diagnosis of North American Nasopharyngeal Carcinoma" Cancer 51: 260-268 (January 1983)	
	BC	Pearson et al. "Identification of an Epstein-Barr Virus Early Gene Encoding a Second Component of the Restricted Early Antigen Complex" Virology 160: 151-161 (1987)	
	BD	Pothan et al., "Identification of T- and B-Cell Epitopes Associated with a Restricted Component of the Epstein-Barr Virus-Induced Early Antigen Complex" Int. J. Cancer 53: 199-204 (1993)	
	BE	Pothan et al., "Human T-Cell Recognition of Epstein-Barr Virus-Induced Replication Antigen Complexes" Int. J. Cancer 49: 656-660 (1991)	
	BF	Rhodes et al., "Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen" J. Immunol Vol. 134, No. 1: 211-216 (January 1985)	
ms	BG	Smith et al., "Antibodies to an Epstein-Barr Virus Nuclear Antigen Synthetic Peptide in Infectious Mononucleosis" Am. J. Clin. Pathology Vol. 92 No. 4: 447-451 (October 1989)	
	BH	Spira et al., "The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay" J. Immunol. Methods 74: 307-315 (1984)	
	BI	Steplewski et al., "Isolation and Characterization of Anti-Monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants" Proc. Natl. Acad. Sci., USA, Vol. 82: 8653-8657 (December 1985)	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 2/15/2003	



Sheet 4 of 5

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ORGU-0023</b>	Serial No. <b>08/392,934</b>
		Applicant <b>R. S. Smith et al.</b>	
		Filing Date <b>October 28, 1996</b>	Group <b>1644</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
BJ	Stewart and Young, "Laboratory Techniques in Solid Phase Peptide Synthesis" Solid Phase Peptides Synthesis (W. H. Freeman & Company, San Francisco, Chapter 2 pages 27-64 (1969)		
BK	Sun et al., "Chimeric Antibodies with 17-1A-Derived Variable and Human Constant Regions" Hybridoma, Vol. 5 Supplement 1: S17-S20 (1986)		
BL	Sutcliffe et al., "Antibodies That React With Predetermined Sites on Proteins" Science Vol. 219, No. 4585: 660-666 (February 1983)		
BM	Tainer et al, "The Reactivity of Anti-Peptide Antibodies is a Function of the Atomic Mobility of Sites in a Protein" Nature 312: 127-134 (November 1984)		
BN	Ulaeto et al, "In Vitro T Cell Responses to a Candidate Epstein-Barr Virus Vaccine: Human CD 4 <sup>+</sup> T-Cell Clones Specific for the Major Envelope Glycoprotein gp340" Eur. J. Immunol. 18: 1689-1697 (1988)		
BO	Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy" Science 252: 1657-1662 (June 1991)		
BP	Wolff et al, "The Use of Monoclonal ANTI-Thy <sub>1</sub> IgG <sub>1</sub> for the Targeting of Liposomes to AKR-A Cells in Vitro and in Vivo" Biochemica et Biophysica Acta, 802: 259-273 (1984)		
BQ	Young "Epstein-Barr Virus" Encyclopedia of Virology, Volume 1, Edited by Webster and Granoff, Academic Press, 404-416 (1994)		
EXAMINER <i>[Signature]</i>		DATE CONSIDERED <i>2/15/2007</i>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>ORGU-0023</b>	Serial No. <b>08/392,934</b>
	Applicant <b>R. S. Smith et al.</b>	
	Filing Date <b>October 28, 1996</b>	Group <b>1644</b>

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
MS	BR	3,654,090	4/4/72	Schuurs et al.	<del>195</del> 435	<del>103.5</del> 7.93
	BS	B1 3,654,090	7/20/82	Schuurs et al.	435 435	7 7.93
	BT	3,850,752	11/26/74	Schuurs et al.	<del>195</del> 435	<del>103.5R</del> 7.93
	BU	4,016,043	4/5/77	Schuurs et al.	<del>195</del> 435	<del>103.5R</del> 5
	BV	4,172,124	10/23/79	Koprowski et al.	<del>424</del> 435	<del>85</del> 70.21
	BW	4,196,265	4/1/80	Koprowski et al.	<del>435</del> 435	<del>2</del> 70.21
	BX	4,629,783	12/16/86	Cosand	<del>530</del> 530	<del>324</del> 324
	BY	<del>4,879,213</del>	<del>11/7/89</del>	<del>Fox et al.</del>	<del>435</del>	<del>5</del>

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	BZ	<del>0 173 254</del>	<del>3/5/86</del>	<del>EPO</del>	<del>X</del>	
MS	CA	0 280 813	9/7/88	EPO	X	
	CB	<del>WO 91/08224</del>	<del>6/13/91</del>	<del>WIPO</del>	<del>X</del>	
MS	CC	WO 94/06470	3/31/94	WIPO		
MS	CD	WO 94/08597	4/28/94	WIPO	X	

EXAMINER <i>MS</i>	DATE CONSIDERED <i>2/15/2007</i>
--------------------	----------------------------------

TECH CENTER 1000 2000

DEC 20 2001

RECEIVED

RECEIVED  
 DEC 04 2002  
 TECH CENTER 1600/2900

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ORGU-0023</b>	Serial No. <b>08/392,934</b>
		Applicant <b>R. S. Smith et al.</b>	
		Filing Date <b>October 28, 1996</b>	Group <b>1644</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AY	Merrifield, "Solid Peptide Synthesis. I. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc. 85: 2149- 2154 (July 1963)	
	AZ	Oi et al., " Chimeric Antibodies", Bio Techniques Vol. 4, No. 3: 214-221 (May/June 1986)	
	BA	<del>Ortho Diagnostic Systems, Inc. ORTHO *Epstein-Barr Virus EA(D+R)-IgG Antibody ELISA Test for Detection of IgG Antibodies to the Early Antigen (EA) Diffuse and Restricted (D&amp;R) Components of the Epstein-Barr Virus (EBV), Product Code 520025, 1-38 (Draft revised August 20, 1993)</del>	
	BB	Pearson et al., "Application of Epstein-Barr Virus (EBV) Serology to the Diagnosis of North American Nasopharyngeal Carcinoma" Cancer 51:260-268 (January 1983)	
	BC	<del>Pearson et al. "Identification of an Epstein-Barr Virus Early Gene Encoding a Second Component of the Restricted Early Antigen Complex" Virology 160:151-161 (1987)</del>	
	BD	<del>Pothen et al. "Identification of T- and B-Cell Epitopes Associated with a Restricted Component of the Epstein-Barr Virus-Induced Early Antigen Complex" Int. J. Cancer 53: 199-204 (1993)</del>	
	BE	<del>Pothen et al., "Human T-Cell Recognition of Epstein Barr Virus-Induced Replication Antigen Complexes" Int. J. Cancer 49: 656-660 (1991)</del>	
	BF	Rhodes et al., "Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen" J. Immunol Vol. 134, No. 1: 211-216 ( January 1985)	
	BG	Smith et al. , "Antibodies to an Epstein-Barr Virus Nuclear Antigen Synthetic Peptide in Infectious Mononucleosis" Am. J. Clin. Pathology Vol. 92 No. 4: 447-451 (October 1989)	
	BH	Spira et al., "The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay" J. Immunol. Methods 74: 307-315 (1984)	
	BI	Steplewski et al., "Isolation and Characterization of Anti-Monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants" Proc. Natl. Acad. Sci., USA, Vol. 82: 8653-8657 (December 1985)	
EXAMINER		DATE CONSIDERED	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ORGU-0023</b>	Serial No. <b>08/392,934</b>
		Applicant <b>R. S. Smith et al.</b>	
		Filing Date <b>October 28, 1996</b>	Group <b>1644</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	BJ	Stewart and Young, "Laboratory Techniques in Solid Phase Peptide Synthesis" Solid Phase Peptides Synthesis (W. H. Freeman & Company, San Francisco, Chapter 2 pages 27-64 (1969)	
	BK	Sun et al., "Chimeric Antibodies with 17-1A-Derived Variable and Human Constant Regions" Hybridoma, Vol. 5 Supplement 1: S17-S20 (1986)	
	BL	Sutcliffe et al., "Antibodies That React With Predetermined Sites on Proteins" Science Vol. 219, No. 4585: 660-666 (February 1983)	
	BM	Tainer et al, "The Reactivity of Anti-Peptide Antibodies is a Function of the Atomic Mobility of Sites in a Protein" Nature 312: 127-134 (November 1984)	
	BN	<del>Ulaeto et al, "In Vitro T Cell Responses to a Candidate Epstein-Barr Virus Vaccine: Human CD 4<sup>+</sup> T Cell Clones Specific for the Major Envelope Glycoprotein gp340"</del> Eur. J. Immunol. 18: 1689-1697 (1988)	
	BO	<del>Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy" Science 252: 1657-1662 (June 1991)</del>	
	BP	Wolff et al, "The Use of Monoclonal ANTI-Thy <sub>1</sub> IgG <sub>1</sub> for the Targeting of Liposomes to AKR-A Cells in Vitro and in Vivo" Biochemica et Biophysica Acta, 802: 259-273 (1984)	
	BQ	Young "Epstein-Barr Virus" Encyclopedia of Virology, Volume 1, Edited by Webster and Granoff, Academic Press, 404-416 (1994)	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

RECEIVED

DEC 04 2002  
TECH CENTER 1600/2900

**Form PTO-1449 Modified**Docket No.  
**ORGU-0023**Serial No.  
**08/392,934**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
**R. S. Smith et al.**U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
**October 28, 1996**Group  
**1644**

TECH CENTER 1500/2900

DEC 04 2002

RECEIVED

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
MS	BR	3,654,090	4/4/72	Schuurs et al.	195	103.5
MS	BS	B1 3,654,090	7/20/82	Schuurs et al.	435	7
MS	BT	3,850,752	11/26/74	Schuurs et al.	195	103.5R
MS	BU	4,016,043	4/5/77	Schuurs et al.	195	103.5R
MS	BV	4,172,124	10/23/79	Koprowski et al.	424	85
MS	BW	4,196,265	4/1/80	Koprowski et al.	435	2
MS	BX	4,629,783	12/16/86	Cosand	530	324
	<del>BY</del>	<del>4,879,213</del>	<del>11/7/89</del>	<del>Fox et al.</del>	<del>435</del>	<del>5</del>

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	<del>BZ</del>	<del>0 173 254</del>	<del>3/5/86</del>	<del>EPO</del>	<del>X</del>	
MS	CA	0 280 813	9/7/88	EPO	X	
	<del>CB</del>	<del>WO 91/08224</del>	<del>6/13/91</del>	<del>WIPO</del>	<del>X</del>	
MS	CC	WO 94/06470	3/31/94	WIPO		
MS	CD	WO 94/08597	4/28/94	WIPO	X	

**EXAMINER****DATE CONSIDERED**



Docket Number (Final)  
7586D4Application Number  
08/392,934INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Smith and Parks

Filing Date

September 15, 1993

Group Art Unit

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4	8	7	9	2	1	3	11/7/89	Fox et al	435		

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	Translation	
												YES	NO
MB)	9	4	0	8	5	9	7	4/28/94	PCT WO	—	—		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MB)	Baer, et al., <i>Nature</i> 310:207, 1984, DNA sequence and expression of the B95-8 Epstein-Barr virus genome
	Rhodes, et al., <i>J. Immunol.</i> , 143:211, 1985, Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen.
	Dillner, <i>J. Proc. Natl. Acad. Sci. U.S.A.</i> , 81:652, 1984, Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen.
	<del>Fox, et al., <i>J. Clin. Lab. Anal.</i>, 1:140, 1987, Synthetic Peptide Derived From the Epstein-Barr Virus Encoded Early Diffuse Antigen (EA-D) Reactive With Human Antibodies</del>
MB S	Lerner, et al., <i>Nature</i> , 299:592, 1982, Tapping the immunological repertoire to produce antibodies of predetermined specificity
	Pothen, et al., <i>Int. J. Cancer</i> , 49:656, 1991, Human T-Cell Recognition of Epstein-Barr Virus-Induced Replication Antigen Complexes.
	Ulaeto, et al., <i>Europ. J. Immunol.</i> , 18:1689, 1988, <i>In vitro</i> T cell responses to a candidate Epstein-Barr virus vaccine: human CD4 <sup>+</sup> T cell clones specific for the major envelope glycoprotein gp340*.
	Pothen, et al., <i>Int. J. Cancer</i> , 53:199 (1993), Identification of T- and B-Cell Epitopes Associated with a Restricted Component of the Epstein-Barr Virus-Induced Early Antigen Complex.
	Ortho Diagnostic Systems, Inc., ORTHO* Epstein-Barr Virus EA(D + R)-IgG Antibody ELISA Test, Product Code 520025, Draft revised 8/20/93
	Gull Laboratories, EBV-EA Test, Product No. EA100 1989

EXAMINER

DATE CONSIDERED

2/2/2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (optional)  
7586D3

Application Number  
08/392,934

Applicant

Smith et al

Filing Date  
September 15, 1993

Group Art Unit

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4	8	7	9	2	1	3	11/7/89	Fox			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	Translation	
												YES	NO
MS MB	0	1	7	3	2	5	4	3/06/86	EPG EP	-	-		
	9	1	0	8	2	2	4	6/13/91	PCT WO	-	-		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MS	Fox, et al., SYNTHETIC PEPTIDE DERIVED FROM THE EPSTEIN-BARR VIRUS ENCODED EARLY DIFFUSE ANTIGEN (EA-D) REACTIVE WITH HUMAN ANTIBODIES, J. of Clinical Laboratory Analysis, 1:140-145 (1987)
	<del>Pearson, G.R., IDENTIFICATION OF AN EPSTEIN-BARR VIRUS EARLY GENE ENCODING A SECOND COMPONENT</del>
	<del>THE RESTRICTED EARLY ANTIGEN COMPLEX, Virology, Vol. 160, June, 1987, pp. 161-161</del>
	<del>Waldmann, T.A., MONOCLONAL ANTIBODIES IN DIAGNOSIS AND THERAPY, Science, Vol. 252,</del>
	<del>June 21, 1991, pp. 1667-1662</del>

EXAMINER

*MS*

DATE CONSIDERED

2/2/2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through cita in conformance and not considered. Include copy of this form with next communication to the applicant.

[illegible]